Literature DB >> 30740449

The issue of how predict survival of patients affected by locally advanced pancreatic cancer.

Benedetto Ielpo1.   

Abstract

Entities:  

Year:  2018        PMID： 30740449      PMCID： PMC6330600          DOI： 10.21037/atm.2018.12.41

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  16 in total

1.  Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

Authors:  Lalitha K Shankar; John M Hoffman; Steve Bacharach; Michael M Graham; Joel Karp; Adriaan A Lammertsma; Steven Larson; David A Mankoff; Barry A Siegel; Annick Van den Abbeele; Jeffrey Yap; Daniel Sullivan
Journal:  J Nucl Med       Date:  2006-06       Impact factor: 10.057

2.  CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy.

Authors:  Woong Sub Koom; Jinsil Seong; Yong Bae Kim; Hae Ok Pyun; Si Young Song
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-08-28       Impact factor: 7.038

3.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

4.  Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades.

Authors:  Jordan M Winter; Murray F Brennan; Laura H Tang; Michael I D'Angelica; Ronald P Dematteo; Yuman Fong; David S Klimstra; William R Jarnagin; Peter J Allen
Journal:  Ann Surg Oncol       Date:  2011-07-15       Impact factor: 5.344

5.  The combination of FDG PET and dynamic contrast-enhanced MRI improves the prediction of disease-free survival in patients with advanced breast cancer after the first cycle of neoadjuvant chemotherapy.

Authors:  Ilhan Lim; Woo Chul Noh; Jihyun Park; Ji Ae Park; Hyun-Ah Kim; Eun-Kyu Kim; Ko Woon Park; Seung Sook Lee; Eun Young You; Kyeong Min Kim; Byung Hyun Byun; Byung Ii Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-06-14       Impact factor: 9.236

6.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.

Authors:  Daniel D Von Hoff; Ramesh K Ramanathan; Mitesh J Borad; Daniel A Laheru; Lon S Smith; Tina E Wood; Ronald L Korn; Neil Desai; Vuong Trieu; Jose L Iglesias; Hui Zhang; Patrick Soon-Shiong; Tao Shi; N V Rajeshkumar; Anirban Maitra; Manuel Hidalgo
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

7.  Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma.

Authors:  B Ielpo; H Duran; E Diaz; I Fabra; R Caruso; V Ferri; L Malavé; M Hidalgo; R Alvarez; C Plaza; Y Quijano; E Vicente
Journal:  Eur J Surg Oncol       Date:  2016-01-29       Impact factor: 4.424

8.  Does the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates?

Authors:  Amanda B Cooper; Abhishek D Parmar; Taylor S Riall; Bruce L Hall; Matthew H G Katz; Thomas A Aloia; Henry A Pitt
Journal:  J Gastrointest Surg       Date:  2014-08-05       Impact factor: 3.452

9.  Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.

Authors:  Pascal Hammel; Florence Huguet; Jean-Luc van Laethem; David Goldstein; Bengt Glimelius; Pascal Artru; Ivan Borbath; Olivier Bouché; Jenny Shannon; Thierry André; Laurent Mineur; Benoist Chibaudel; Franck Bonnetain; Christophe Louvet
Journal:  JAMA       Date:  2016-05-03       Impact factor: 56.272

10.  Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy.

Authors:  Hye Jin Choi; Jeong Won Lee; Beodeul Kang; Si Young Song; Jong Doo Lee; Jae-Hoon Lee
Journal:  Yonsei Med J       Date:  2014-11       Impact factor: 2.759
View more
  1 in total

Review 1.  Central vascular ligation and mesentery based abdominal surgery.

Authors:  M Franceschilli; D Vinci; S Di Carlo; B Sensi; L Siragusa; A Guida; P Rossi; V Bellato; R Caronna; S Sibio
Journal:  Discov Oncol       Date:  2021-08-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.